Question 1

Which IGF-1 produced the published results?

Accepted Answer

Two molecules share the name, and the record splits cleanly between them. Mecasermin is a lab-made copy of the hormone, approved in the US for the long-term treatment of growth failure in children with severe primary IGF-I deficiency. Almost every human measurement belongs to it. The other is IGF-1 LR3, which a 2026 review lists among the IGF-1 analogues found in online self-administration protocols. A 2023 paper made both proteins in a yeast system and reports that purified IGF-1 and LR3 IGF-1 show bioactivity comparable to the standard IGF-1. That shows the two behave alike in a dish. It does not establish that a clinical figure produced by one describes the other, and that split governs every number below.

Question 2

What did the sheep and cell experiments record as an outcome?

Accepted Answer

Three measurements, and not one of them is an appearance. A 2003 experiment in near-term fetal sheep tracked how often a heart cell divided, how large it grew and how many nuclei it ended up with, and reports that in culture, LR3 IGF-1 increased myocyte bromodeoxyuridine (BrdU) uptake by three- to five-fold, which is a marker of cells copying their own genetic material before dividing. The same experiment also reports that LR3 IGF-1 did not increase footprint area, which is the measure of how large the cell actually became. A 2020 study in the same animal followed the blood supply instead, and found that coronary conductance was preserved on a per-gram basis following IGF-1 treatment. More cells, no larger cells, and a blood supply keeping pace is the entire measured outcome set for this analogue.

Question 3

What did the clinics write down when the medicine was given to people?

Accepted Answer

Height, mostly, with a few blood markers beside it. The trial supporting the US approval was a noncomparative, multicenter trial (n = 76), and it recorded that during the first year of treatment, height velocity significantly increased from a mean 2.8 cm/year at baseline to a mean 8.0 cm/year in those children. Height velocity is centimetres of growth over a year, read against the same child's earlier rate rather than against anybody else. A 2023 study of children with IGF-1 deficiency added a laboratory measure, and selected stem cells were analyzed in peripheral blood flow cytometrically alongside growth. In Rett syndrome the instrument changed again, to breathing, because the phase I work read their plethysmography-based apnoea index, a count of pauses taken from a device that measures airflow. Centimetres, blood counts and breathing pauses are what the clinics actually wrote down.

Question 4

How long did anything take to show up in those trials?

Accepted Answer

The published intervals run in years rather than weeks, and they belong to children on a prescription. The approval trial read its first growth figure at twelve months, and mean growth velocities remained above baseline for up to 8 years in that group of children. A separate paediatric group was monitored for 4-5 years of rhIGF-1 treatment while blood measures were taken alongside height. The shortest clinical reading in this record is the Rett syndrome work, which was a 20-weeks phase I open label trial of mecasermin (recombinant human IGF-1) in children with RTT. So the honest answer to how long IGF-1 takes is that the shortest published interval among the sources covered here is twenty weeks, in nine children, for a breathing measure. Muscle in an adult and height in a child are different questions, and the second is the one with a clock attached to it.

Question 5

Why did the open-label result not survive the randomised trial?

Accepted Answer

Because an open-label trial and a randomised one are answering different questions, and IGF-1 is one of the few compounds where both answers were published. A 20-weeks phase I open label trial of mecasermin (recombinant human IGF-1) in children with RTT demonstrated significant improvements in breathing phenotypes. The follow-up was built to test exactly that, and a subsequent randomised controlled phase II trial did not show significant improvements in primary outcomes although two secondary clinical endpoints showed positive changes. Nothing about the first trial was dishonest. Everyone in it knew who was receiving what, there was nobody untreated to measure against, and the improvement that appeared did not hold once those two conditions were supplied. A before-and-after pair has neither condition either, which puts it with the first result rather than the second.

Question 6

Did everyone in the trials respond the same way?

Accepted Answer

They did not, and two of these studies measured the disagreement directly. In the Rett syndrome work the children were sorted by their breathing into a responder group and everybody else. That group displayed significantly different transcript profiles, which is to say a different set of genes was switched on in their blood. A 2025 review of the same condition goes further, finding that genetic background modulates therapeutic response. In the growth work the split is plain arithmetic, because children on the medicine were achieving at least proper rate of growth (compared to healthy group) in 80% of subjects. That leaves one child in five outside the headline figure. A published average is a summary of people who did not all agree with each other.

Question 7

Why does an open growth plate matter to a before and after?

Accepted Answer

Because every measured growth result in this record came from a skeleton that had not finished growing. A Canadian reimbursement review advises coverage only for children carrying a confirmed diagnosis and in whom epiphyseal growth plates have not yet closed, and that condition is what makes height velocity measurable in the first place. Growth plates are the cartilage zones at the ends of the long bones, and they fuse at the end of puberty. An adult reading a height-velocity figure is reading an outcome that stopped being available to them years earlier. That does not make the compound inert in an adult. It means the instrument behind the published numbers cannot be pointed at one, and the amounts those numbers came from are handled separately at the IGF-1 dosage page.

Question 8

Is a before-and-after photograph a result for IGF-1 LR3?

Accepted Answer

It is a record of how somebody looked, taken at an interval they chose, with nothing standing beside it for comparison. The measured record for this analogue runs to cell division in a dish and heart growth in fetal sheep, and a 2023 paper reports that human IGF-1 and its analog Long R3 IGF-1 (LR3 IGF-1) are recombinant expressed and produced in the Pichia pastoris (P. pastoris) expression system, which is a manufacturing result rather than a bodily one. A 2026 review grades peptides by the evidence behind each one, and the bottom of its scale is a complete absence of human studies. So a photograph is not competing against a weak human result, because among the sources covered here there is no human result for IGF-1 LR3 for it to compete with. Reading it as evidence means reading the only thing available rather than something that measures what it appears to measure.

Question 9

Can IGF-1 LR3 reviews and posted logs be read as results?

Accepted Answer

They can be read as what somebody went through, and not as a measurement, for a reason that does not apply to an approved medicine. A 2026 review describes uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains. So a posted log reports an outcome from material whose identity and strength nobody checked. The same review is written for clinicians trying to read symptoms in people following online self-administration protocols, which is a very different job from grading a result. A log also tends to record a stack rather than one compound, and that removes the last chance of pinning a change on anything. What a reader ends up with is an account of a change, attached to a substance nobody named, over a span nobody fixed.

Question 10

Why does a growth signal cut both ways?

Accepted Answer

Because the activity that would produce a visible result is the activity the clinical reviews flag. In a cell culture, LR3 IGF-1 increased myocyte bromodeoxyuridine uptake three- to five-fold. That is cells dividing faster than they would on their own. A 2009 review of the approved medicine states that the anti-apoptotic properties of IGF-I are implicated in cancer pathogenesis-a concern for long-term therapy. Anti-apoptotic here means cells marked for disposal keep going. A 2026 review of the unregulated market records the same point as biologically plausible but unproven mitogenic concerns, and mitogenic means prompting cells to divide. Neither review gives a measured rate in anybody taking this analogue. The gap between a mechanism and a rate is the whole of what is being reported, and the documented harm record is laid out at the IGF-1 safety page.

Question 11

Is IGF-1 LR3 worth it?

Accepted Answer

That is a decision, and it is not ours to make. What the record can supply is where this compound sits and what a figure from it would be worth once somebody produced one. A 2026 review places the category on a scale of evidence tiers from regulatory-grade randomized trial data to a complete absence of human studies, and notes the absence of regulatory approval for physique- or performance-related indications. The clinical evidence that does exist belongs to a different molecule, given to children with a rare deficiency, and measured in centimetres of height. There is also a precedent for enthusiasm running ahead of measurement in exactly this family: a 2009 review records that promotion of rhIGF-I for treatment of idiopathic short stature has been intensive, with neither data nor rationale suggesting that there might be a better response than has been documented with rhGH. Those are the two things a reader is weighing.

Question 12

What would an IGF-1 LR3 result have to look like to count?

Accepted Answer

Four things, and this record shows what happens whenever one of them goes missing. A result would need a measurement taken before anything began, a comparable group given nothing, an instrument chosen in advance, and a reading date chosen in advance. The growth work lacked the comparison group, and the single randomised trial in this literature reversed the open-label finding it had been built to confirm. A 2006 review of the binding-protein version states that there are no published data on the efficacy of mecasermin rinfabate in treating growth disorders, which is the same gap written down by the people closest to it. A 2025 systematic review closes by underscoring the necessity of larger, rigorously designed trials. Until a trial of that shape is run on this analogue, a photograph and a published figure are describing different things rather than the same thing at different quality.

IGF-1: reported results by outcome